References
- Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75:Suppl 191 - 202; http://dx.doi.org/10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; PMID: 8000996
- Reppert S, Boross I, Koslowski M, Türeci Ö, Koch S, Lehr HA, et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2011; 2:600; http://dx.doi.org/10.1038/ncomms1609; PMID: 22186896
- Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010; 101:2384 - 90; http://dx.doi.org/10.1111/j.1349-7006.2010.01684.x; PMID: 20825419
- Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011; 34:149 - 62; http://dx.doi.org/10.1016/j.immuni.2011.02.012; PMID: 21349428
- Hwang ES. Transcriptional regulation of T helper 17 cell differentiation. Yonsei Med J 2010; 51:484 - 91; http://dx.doi.org/10.3349/ymj.2010.51.4.484; PMID: 20499411
- Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836 - 48; http://dx.doi.org/10.1038/nri1961; PMID: 17063185
- Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295:338 - 42; http://dx.doi.org/10.1126/science.1065543; PMID: 11786644